What AACR 2026 Revealed About the Future of Cancer Research
From functional precision medicine to more human-relevant models, AACR 2026 highlighted a field moving beyond awareness and toward practical implementation. Here are the themes that stood out most to Inventia Life Science.
AACR 2026 made one thing clear: cancer research is entering a more applied phase.
Across scientific sessions, poster halls, and booth conversations, the discussion has moved beyond whether more advanced models are needed. Researchers increasingly accept that conventional systems alone are not enough, and the more pressing question now is how to implement biologically relevant, scalable workflows that can support real discovery decisions.
That shift was visible across multiple fronts. Interest in organoids and tumor microenvironment biology remains strong, functional precision medicine is gaining momentum, and New Approach Methodologies, or NAMs, are moving from abstract concept to strategic priority. As AI becomes more embedded in oncology R&D, the need for high-quality experimental biology is becoming even more important, not less.
For us, AACR 2026 sharpened a direction that was already emerging across cancer research.
The conversation has moved from “why 3D” to “how do I use it?”
At AACR 2026, conversations around 3D models felt noticeably more mature. Researchers were focused less on making the case for 3D and more on practical questions: how to build the right model for a specific cancer question, how to improve reproducibility, how to integrate 3D systems into downstream assays, and how to make those workflows fit the realities of discovery and translational research. The conversations were noticeably more application-driven, with researchers looking for specific solutions they could map onto their own workflows.
Morgan Hamon, PhD, Technical Sales Specialist at Inventia Life Science, saw that shift very clearly on the conference floor. “After more than 20 years working in the 3D cell culture field, this was the first time people approached me with a clear need rather than polite curiosity,” he said. “The conversation has definitely shifted from ‘why 3D?’ to ‘how do I implement it?’ Most discussions focused on understanding the advantages of our system and how it could fit into their research workflows.” At the same time, he noted that there is still a strong need for education, particularly around organoids, NAMs, and the distinctions between different types of 3D systems.
Ali McCorkindale, PhD, Principal Scientist at Inventia Life Science, observed something similar from a scientific perspective. She noted that conversations moved much faster into specific use cases than at previous meetings, particularly around organoids, tumor microenvironment biology, and patient-derived systems, with researchers focused on how 3D models could be integrated into downstream assays rather than treated as standalone tools.
This is an important inflection point for the field. It suggests that 3D biology is no longer viewed as a niche capability or an exploratory add-on. It is increasingly expected to function as part of a broader workflow.
Functional precision medicine is becoming a central theme
Another major theme at AACR 2026 was the growing emphasis on functional precision medicine.
Across multiple sessions, there was a clear sense that genomics alone remains insufficient for many clinical and translational decisions. Actionable mutations are still identified in only a subset of patients, and even when they are, they do not always predict therapeutic response with enough confidence.In response, the field is placing greater value on directly testing therapies in patient-derived systems and combining those functional results with genomic and transcriptomic information. That shift was clear throughout the meeting, with growing emphasis on directly testing therapeutic hypotheses in patient-derived material rather than relying solely on genomic markers.
Ali put it this way: “There was a clear recognition that genomics alone does not fully explain treatment response, and that researchers need to complement molecular profiling with direct functional testing on patient-derived material. That shift naturally increases the need for model systems that can preserve tumor complexity while supporting pharmacological testing, genomic analysis, and transcriptomic readouts.”
This matters because it changes what researchers need from preclinical models. It is no longer enough for a system to be biologically interesting. It must also support decision-making. That means generating data that is reproducible, interpretable, and relevant to the specific therapeutic question at hand.
Tumor complexity is no longer optional
AACR 2026 also reinforced a broader recognition that tumor biology cannot be reduced to malignant cells alone.
Across the meeting, there was strong interest in model systems that better capture the complexity of the tumor microenvironment, including stromal and immune components. Researchers were clearly thinking beyond malignant cells alone and toward systems that can reflect the broader ecosystem shaping disease progression and therapeutic response. Together, these discussions pointed to a more integrated view of cancer, not as a single-cell problem, but as a dynamic biological system.
Morgan described this as one of the defining themes of the meeting. “For me, the central theme throughout AACR 2026 was the importance of the 3D aspect of cell culture,” he said. “From there, discussions naturally expanded into related topics such as co-culture approaches to better represent tumor complexity, as well as the critical role of extracellular matrix components and physical cues, like stiffness, in achieving more physiologically relevant cell phenotypes and thus, better cancer models.”
This shift has practical implications. As researchers look to model therapeutic response more faithfully, they are increasingly seeking systems that can capture tumor heterogeneity, cellular interaction, and microenvironmental influence in a controlled and reproducible way.
That is also why “more complex” is not enough on its own. The value of complexity depends on whether it can be generated consistently and linked to meaningful downstream readouts.
NAMs are gaining visibility, but implementation is still uneven
AACR 2026 made it clear that NAMs are becoming a more visible part of the research conversation. Awareness is growing across both academia and pharma, and there were clear signals that human-relevant research approaches and functional assays are becoming more important in how the field thinks about future research design and funding priorities.
At the same time, adoption remains uneven. For some groups, NAMs still feel like an emerging priority or a strategic buzzword. For others, they are already becoming embedded into real workflows and research planning. That gap between awareness and implementation creates both a challenge and an opportunity.
Morgan’s poster conversations reflected this tension directly. “A recurring topic was the growing need to follow FDA guidelines around New Approach Methodologies,” he said, noting that several researchers mentioned they were now expected to integrate more biologically relevant models into their studies. But he also observed that many people were still trying to work out how to adopt those models in practice, including what equipment they would need and how to analyze 3D results within existing workflows.
That is the challenge. Many labs are still early in their journey and need practical guidance. But it is also the opportunity: to move beyond abstract discussion and focus on what makes a model useful in practice, including biological relevance, reproducibility, scalability, and compatibility with downstream assays.
AI is raising the bar for experimental biology
AI was another strong theme at AACR 2026, but the most interesting signal was not simply that AI is growing. It was the way AI is converging with experimental biology.
One of the clearest shifts was the move toward more iterative, experimentally anchored workflows, where AI models are refined through ongoing feedback from biologically relevant systems. That matters because AI models are only as useful as the data they are trained on, and reductionist or poorly structured datasets can quickly limit translational value. Across the meeting, there was growing emphasis on foundational models, integrated AI environments, and the need for diverse, high-quality biological data.
Ali said the AI discussions reinforced one of the broader scientific messages of the conference. “AI is becoming increasingly embedded in oncology R&D, but the more compelling direction was the move away from static prediction and toward iterative, experimentally anchored workflows,” she said. “In that context, reproducible 3D systems have an important role to play as high-quality data generation engines, supporting ‘lab-in-the-loop’ approaches where biological data can be used to train, refine, and validate computational models.”
For cancer research, that raises the standard for preclinical systems. Models now need to do more than support one experiment at a time. They increasingly need to generate structured, reproducible outputs that can feed into broader analytical and AI-enabled workflows.
In that sense, the rise of AI does not reduce the importance of model quality. It makes it more important.
The real opportunity now is workflow, not just model generation
Taken together, the strongest message from AACR 2026 was not simply that advanced models matter. It was that workflows matter.
Researchers want systems that fit into real discovery programs. They want to move from 2D into 3D without sacrificing throughput. They want more representative models without introducing unmanageable variability. They want to connect phenotypic response with molecular readouts. And they want workflows that can support screening, validation, and increasingly, patient-relevant testing.
Ali heard that repeatedly during poster sessions. “The most common questions were very practical,” she said. “Researchers wanted to know how to move from 2D into 3D without losing throughput, reproducibility, or compatibility with the assays they already rely on.” She also noted strong interest in organoid workflows and in combining drug testing with genomic or transcriptomic readouts while keeping systems scalable and reproducible.
Morgan heard similar concerns during poster sessions, particularly around compatibility with current lab practices, equipment requirements, and how to analyze results from 3D systems within existing workflows.
That is where the field appears to be headed next. The expectation is not only that 3D models be biologically relevant, but that they be integrated into downstream workflows such as screening and validation rather than treated as standalone systems.
The most valuable model systems will not be those that are simply more complex. They will be the ones that make complex biology more usable.
Looking ahead
AACR 2026 reinforced that cancer research is becoming more functional, more integrated, and more human relevant.
The field is moving beyond the early adoption phase for 3D biology and into a more practical stage defined by implementation, reproducibility, and translational utility. Functional precision medicine is gaining traction. Tumor complexity is becoming central to model design. NAMs are becoming more visible in research strategy. And AI is increasing demand for biologically relevant data that can support iterative discovery.
For those of us working in this space, that is an exciting shift. It points toward a future where better cancer models are not just more sophisticated. They are more useful.
And that may be the most important takeaway of all.
Explore the AACR 2026 Posters
Looking for the data behind these themes? Explore the four posters Inventia Life Science presented at AACR 2026: